Non-Alcoholic Fatty Liver Disease: Current Perspectives and Future Direction in Disease pathogenesis, Treatment and Diagnosis
Shaminie Athinarayanan and Wanqing Liu*
Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University. West Lafayette, IN 47907, USA
- *Corresponding Author:
- Wanqing Liu, Ph.D
Department of Medicinal Chemistry and Molecular Pharmacology College of Pharmacy
Purdue University Room 224B, RHPH Building, 575 Stadium Mall
Dr., West Lafayette, IN 47907, USA
E-mail: [email protected]urdue.edu
Received date: July 24, 2012; Accepted date: August 01, 2012; Published date: August 03, 2012
Citation: Athinarayanan S, Liu W (2012) Non-Alcoholic Fatty Liver Disease: Current Perspectives and Future Direction in Disease pathogenesis, Treatment and Diagnosis. Med chem 2:e104. doi:10.4172/2161-0444.1000e104
Copyright: © 2012 Athinarayanan S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the world. An important implication of this disease is the progression of the disease to a more complicated condition called non-alcoholic steatohepatitis (NASH) and the wide variety of clinical presentations. Over the past 5 years, remarkable progresses have been made in understanding the genetic basis for the disease. Recent clinical trials in pharmacotherapy for the disease have been encouraging as well. It is anticipated that the integration of the wide spectrum information retrieved from genomics, transcriptomics and proteomics studies conducted in NAFLD and NASH will mediate a better understanding of the disease pathogenesis and facilitate the postulation of disease pathobiology pathways. Genetic and biological markers identified from the omics studies may hold promise for diagnosis, personalized treatment, early prevention and new drug development.